|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00460 SIHUAN PHARM
Nominal 
0.660 +0.050 (+8.197%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 1,901,109 | 2.181% | 1,860,539 | 2,181,189 | 3,291,270 | 2,464,226 |
| Cost of Sales | (659,399) | 16.729% | (564,895) | (693,608) | (842,754) | (549,777) |
| Gross Profit | 1,241,710 | -4.163% | 1,295,644 | 1,487,581 | 2,448,516 | 1,914,449 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | (1,727,119) | (131,297) | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | 59,228 | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | 72,307 | |
| Share of Results of Asso. & JCEs | (15,226) | -71.604% | (53,621) | (80,875) | (158,581) | (13,064) | |
| Profit / (Loss) before Taxation | (428,288) | 165.588% | (161,260) | (2,122,778) | 486,049 | 765,844 | |
| Taxation | (43,261) | -55.136% | (96,427) | (196,794) | (253,279) | (219,040) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | 36,296 | -- | (34,917) | |
| Non-controlling Interests | 254,887 | 25.147% | 203,670 | 368,358 | 183,739 | (38,505) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (216,662) | 301.100% | (54,017) | (1,914,918) | 416,509 | 473,382 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 99,383 | -18.155% | 121,429 | 64,382 | (44,637) | (127,511) |
| Depreciation & Amortisation | 84,995 | 6.597% | 79,735 | 99,150 | 301,463 | 265,225 |
| Directors' Emoluments | -- | -- | 18,497 | 17,937 | 26,895 | 24,153 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -2.340 | 303.448% | -0.580 | -20.520 | 4.420 | 5.000 |
| DPS (cts) | 1.900 | -- | 0.000 | 6.500 | 10.800 | 15.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | 244.344% | 300.000% |
| Cash flow per share ($) | -- | -- | 0.021 | 0.005 | 0.071 | 0.024 |
| NBV per share ($) | 0.470 | -- | 0.475 | 0.508 | 0.888 | 0.971 |
| Remarks: | Real time quote last updated: 02/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -216,662 |
| %Change | 301.100% |
| EPS / (LPS) | RMB -0.023 |
| NBV Per Share (¥) | RMB 0.470 |